Skip to content

Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive

Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02531581
Enrollment
60
Registered
2015-08-24
Start date
2015-12-23
Completion date
2020-04-09
Last updated
2020-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Brief summary

Pulmonary embolism (PE) is a serious disease with frequent intra hospital mortality remains high. If anticoagulation is perfectly codified, the remainder of the initial management has been less studied. In particular, the conditioning Initial often involves systematic plasma volume of 250 to 500 cc, by analogy to other situations. But this treatment option is not based on factual data. In the right ventricular dysfunction that often accompany severe EP, volume expansion may instead be harmful, according to the law of Frank Starling. A retrospective study has recently shown a benefit of diuretic therapy in patients hospitalized for severe normotensive EP. The proposed study is interventional, prospective, multicenter, randomized, require to include 60 patients. The main objective of the study is the comparison of the troponin normalization period Ic (biomarker of right ventricular dysfunction) in patients hospitalized in the initial phase of a serious normotensive EP, between the 2 groups diuretic and filling Vascular. The primary endpoint is the time in hours standardization of troponin Ic. The secondary endpoints will be: * the period of normalization of Brain Natriuretic Peptide (BNP) * changes in echocardiographic parameters of right ventricular dysfunction * a composite endpoint: cardiovascular death / cardiogenic shock / use of amines / use of thrombolysis.

Detailed description

Main objective: Compared with the time of normalization of cTnI (biomarker of right ventricular dysfunction) in hospitalized patients in the initial phase of a serious EP normotensive between the 2 groups diuretic and vascular filling PRINCIPAL INCLUSION CRITERIA * older than 18 Patient * Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by a chest CT) The serious nature without hypotension is defined by the presence of: * From biological criteria: troponin and / or BNP positive AND * In sonographic criteria: dilated right ventricle defined by echocardiography right over left ventricle ratio (VG)\> 0.9 in apical 4- chamber or 0.7 in large parasternal axis and right ventricular systolic dysfunction (TAPSE \<16 mm and S 'pulsed TDI tricuspid \<10 cm / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial Pressure with systolic (PAPs)\> 35 mmHg or paradoxical septum * Informed consent signed * Affiliation to social security PRINCIPAL EXCLUSION CRITERIA * Thrombolysis before inclusion * State of cardiogenic shock defined as systolic BP \<90 mmHg or a drop of\> 40 mmHg in systolic BP for\> 15 minutes * severe chronic renal impairment defined by clearance \<30 ml / min. * pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier: cthC5Fc14NkHBXHkFCiTvGcJ8a8= Page 15/26 women of childbearing age and the results will be communicated to the patient by a doctor of his choice) * Most People under guardianship * hospitalized without their consent and not protected by law No * Private person of liberty * Residence time of more than 24 hours in another department after the positive diagnosis of pulmonary embolism

Interventions

DRUGFurosemide

furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc

DRUGNaCl 9% isotonic

normal saline 500 cc / 4 hours and 1 L / 24 hours

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by a chest CT) The serious nature without hypotension is defined by the presence of: * From biological criteria: troponin and / or BNP positive AND * In sonographic criteria: dilated right ventricle defined by echocardiography right over left ventricle ratio (VG)\> 0.9 in apical 4- chamber or 0.7 in large parasternal axis and right ventricular systolic dysfunction (TAPSE \<16 mm and S 'pulsed TDI tricuspid \<10 cm / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial Pressure with systolic (PAPs)\> 35 mmHg or paradoxical septum * Informed consent signed * Affiliation to social security

Exclusion criteria

* Thrombolysis before inclusion * State of cardiogenic shock defined as systolic BP \<90 mmHg or a drop of\> 40 mmHg in systolic BP for\> 15 minutes * severe chronic renal impairment defined by clearance \<30 ml / min. * pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier: cthC5Fc14NkHBXHkFCiTvGcJ8a8= * women of childbearing age and the results will be communicated to the patient by a doctor of his choice) * Most People under guardianship * hospitalized without their consent and not protected by law No * Private person of liberty * Residence time of more than 24 hours in another

Design outcomes

Primary

MeasureTime frameDescription
Time normalization hours Troponin Ic.participants will be followed for the duration of hospital stay, an expected average of 12 hoursThis is a direct assay on peripheral venous sampling, easy to collect, accurate and reproducible, made routines in biochemistry laboratories CHU Nice and Antibes CH. Assay kits are the same at the University Hospital of Nice and Antibes CH (BECKMANTM kit). The threshold of positivity of troponin is 0.07 ng / mL.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026